CD14+ monocytes, M2-type polarized macrophages, Phenotyping and cell viability (basal)
MONO-0013- Context
- Descriptions
- Requirement
- Study and reporting
- See also
Monocytes and macrophages are the first defenses against pathogens and take part in the regulation of adaptive immune response. Circulating monocytes enter injured and inflamed peripheral tissues where they differentiate into different types of resident macrophages. As for T helper cells (Th), macrophages are classified into two categories: type 1 macrophages, which are classically activated (M1), and type 2 macrophages that are activated in a more specific way. M1 macrophages are characterized by a proinflammatory phenotype and an anti-microbial activity. M2 macrophages are involved in angiogenesis, reparation as well as in the matrix remodeling process. This in vitro assay is performed on CD14+ human monocytes in order to evaluate, by using flow cytometry, the capacity of compounds to induce the polarization of monocytes into M2 macrophages (M-CSF like effect) by phenotype analysis (measurement of the expression level of CD80 and CD163 markers associated with cell viability control).
| Biological Model | CD14+ monocytes |
|---|---|
| Species | Human |
| EndPoint | CD80 and CD163 phenotyping and cell viability (TOPRO-3) |
| Method | Flow cytometry |
| Stimulation Factor | Basal |
| Compound Reference | M-CSF |
| Physiopathology | Blood and lymphatic system, cardiovascular system and immunity > Immuno-inflammation assays using blood/immune cells > Monocytes/macrophages |
Feasibility, study proposal:
Our sales team is here to help you find solutions:
Price: our pricing system consists of a fixed price per study + pricing per unit (price per replicate or experimental condition)
Start of assays and turnaround time: the start of an assay is subject to the receipt of your agreement and of the compounds to be tested. The sending date of the study report is communicated by email when the study starts. Although of an average of 5 to 10 weeks, our turnaround time may be subject to some fluctuation (due to availability of biological samples, to workload, etc.).
Required quantity of compounds: the required quantity is generally of a few mg or ml but may vary according to the form and solubility of compounds and to the concentrations to be tested. Please contact us for an estimation.
Customized protocols: for this assay, as for all of our assays, we can develop a protocol adapted to your needs. Should you have any question, please contact us.
Our sales team is here to help you find solutions:
- Technical feasibility study of your project
- Development of an assay selection strategy
- Definition of an experimental scheme
- Financial assessment and contractual agreements (costs, turnaround time, non-disclosure agreements, etc.)
Price: our pricing system consists of a fixed price per study + pricing per unit (price per replicate or experimental condition)
Start of assays and turnaround time: the start of an assay is subject to the receipt of your agreement and of the compounds to be tested. The sending date of the study report is communicated by email when the study starts. Although of an average of 5 to 10 weeks, our turnaround time may be subject to some fluctuation (due to availability of biological samples, to workload, etc.).
Required quantity of compounds: the required quantity is generally of a few mg or ml but may vary according to the form and solubility of compounds and to the concentrations to be tested. Please contact us for an estimation.
Customized protocols: for this assay, as for all of our assays, we can develop a protocol adapted to your needs. Should you have any question, please contact us.
Study management: each project requires advice and expertise so each study is managed and monitored by a dedicated study director who will be attentive to all your needs and questions.
Validation: the assays listed in the catalogue have undergone a preliminary validation and are subject to Standard Operating Procedures (SOPs) and to validation criteria. However, the robustness of each assay may be different according to the models and to the analytical methods. Please do not hesitate to contact us for more information.
Report and experimental data: our services include the writing of a study report in English or in French. This scientific report is provided in a PDF or Microsoft® Office format.
Laboratory / Location: this assay (as all of our assays) will be carried out in our Gençay laboratory in France.
Validation: the assays listed in the catalogue have undergone a preliminary validation and are subject to Standard Operating Procedures (SOPs) and to validation criteria. However, the robustness of each assay may be different according to the models and to the analytical methods. Please do not hesitate to contact us for more information.
Report and experimental data: our services include the writing of a study report in English or in French. This scientific report is provided in a PDF or Microsoft® Office format.
Laboratory / Location: this assay (as all of our assays) will be carried out in our Gençay laboratory in France.
| Reference | Title | EndPoint | Method |
|---|---|---|---|
| Reference | Title | EndPoint | Method |
| CD19BL-0005 | CD19+ B cells, phenotyping & proliferation (basal) | Proliferation | Flow cytometry [3H]-thymidine incorporation |
| MONO-0015 | CD14+ monocytes, Cytokine release (basal) | *** (must be login) | *** (must be login) |
| PBMC-0042 | PBMC, M2-type macrophage induction in a MLR (Mix Lymphocyte Reaction) culture (basal) | *** (must be login) | *** (must be login) |
| PBMC_Lb-0002 | PBMC, arachidonic acid metabolite release (A23187 stimulation) | *** (must be login) | *** (must be login) |
| PBMC_Lb-0001 | PBMC, PGE2 release (LPS stimulation) | *** (must be login) | *** (must be login) |
| THP1-0007 | THP-1, IL-1 beta release (LPS stimulation) | *** (must be login) | *** (must be login) |
| MONO-0004 | Monocytes, opioid receptor labeling (Basal) | ChemR23 expression delta-opioid receptor (DOR) expression Delta-type opioid receptor 1 (OPRD1) expression GPR120 expression mu -opioid receptor (MOR) expression | Flow cytometry |
| MONO-0009 | CD14+ monocytes, Cytokine release (basal) | IL-1 beta, IL-6, IL-8, TNF- alpha release | Flow cytometry (multiplex) |
| MONO-0014 | Activated M2 macrophages, Switch towards M1 macrophages (basal) | CD80 and CD163 phenotyping and cell viability TNF- alpha, IL-6, IL-12p70 release | Flow cytometry |
| MONO-0007 | M1 macrophages, Phenotyping and/or Cytokine release (IFN- gamma + LPS stimulation) | CD80 and CD163 phenotyping and cell viability TNF- alpha, IL1 beta, IL-6, IL-10, IL12p70 release | Flow cytometry (multiplex) |
